Nurse Practitioner Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Jenna Comstock

Nurse Practitioner South Sioux City, NE Nurse Practitioner

NPI 1265159305 CMS profile 11404846

3250 Plaza Dr, South Sioux City, NE 68776

Open in the dashboard

General payments

$3,414

231 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jenna Comstock of South Sioux City, NE is reported in the CMS Open Payments database as having received $3,414 across 231 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,207 75
2024 General $1,077 69
2023 General $1,036 81
2022 General $94 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jenna Comstock
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Jenna Comstock were reported at $1,207. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Jenna Comstock Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $0 $135 $40–$426 $132
2022 $94 $152 $48–$470 $149
2023 $1,036 $166 $54–$529 $160
2024 $1,077 $173 $55–$556 $164
2025 $1,207 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. AbbVie, Inc. $570 45 payments
  2. Pfizer Inc. $519 38 payments
  3. AstraZeneca Pharmaceuticals LP $486 26 payments
  4. Novo Nordisk Inc $482 33 payments
  5. Lilly USA, LLC $203 20 payments
  6. Bayer HealthCare Pharmaceuticals Inc. $173 9 payments
  7. Astellas Pharma US Inc $106 7 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $86 5 payments
  9. Radius Health, Inc. $85 6 payments
  10. Merck Sharp & Dohme Corporation $83 5 payments
  11. Other $621 37 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $3,400 230 payments
  2. Education $14 1 payment
Products named General payments · program years 2022–2025
  1. Ozempic $407 29 payments
  2. RYBELSUS $337 25 payments
  3. NURTEC ODT $246 20 payments
  4. VRAYLAR $235 20 payments
  5. ELIQUIS $228 15 payments
  6. ZAVZPRET $213 17 payments
  7. UBRELVY $160 12 payments
  8. Kerendia $150 8 payments
  9. FARXIGA $146 7 payments
  10. QULIPTA $132 10 payments
  11. Other $2,344 152 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

646

Median for Nurse Practitioner: 389

Drug cost

$17,047

Median for Nurse Practitioner: $21,885

Branded share of claims

25.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vraylar Cariprazine Hcl Brand 14 $9,064
Vyvanse Lisdexamfetamine Dimesylate Brand 11 $1,943
Omeprazole Generic 22 $769
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 38 $656
Cefdinir Generic 30 $600
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 20 $551
Cephalexin Generic 81 $465
Tramadol Hcl Generic 24 $440
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 42 $439
Pantoprazole Sodium Generic 24 $377

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 81 billing codes

Paid by Medicare

$33,254

Of which drugs: $4,592

Medicare patients

269

Average age 74

Services billed

1,590

176 women, 93 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 38%
Diabetes 23%
Chronic kidney disease 20%
COPD 20%
Depression 19%
Osteoporosis 19%
Ischemic heart disease 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, ceftriaxone sodium, per 250 mg J0696 Office 12 52 $18

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 26 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $117
$117 14 —
ELIQUIS
  • PFIZER INC. $87
$87 — —
RYBELSUS
  • Novo Nordisk Inc $81
$81 — —
Ozempic
  • Novo Nordisk Inc $81
$81 — —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $56
$56 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 26 with Patron

Records

231 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Nebraska

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record